BioCentury | Apr 7, 2017
Company News

Jazz, Hikma deal

...the last of which expires in March 2033. It has already settled patent litigation with Wockhardt Ltd....
BioCentury | Apr 6, 2017
Company News

Jazz, Hikma settle Xyrem patent litigation

...the last of which expires in March 2033. It has already settled patent litigation with Wockhardt Ltd....
BioCentury | Oct 28, 2016
Company News

Cempra falls on FDA's manufacturing concerns

...said it believes FDA's concerns are related to GMP systems at "several" facilities operated by Wockhardt Ltd....
BioCentury | May 16, 2016
Analyst Picks & Changes

Analyst picks & changes

...from $137 after Jazz settled two patent infringement suits regarding Xyrem sodium oxybate. Jazz granted Wockhardt Ltd....
BioCentury | Sep 15, 2014
Clinical News

WCK 2349 regulatory update

...pneumonia (HAP). Early next year, Wockhardt plans to start Phase III testing of both compounds. Wockhardt...
...WCK 771 is an IV tricyclic fluoroquinolone, and WCK 2349 is an oral broad-spectrum antibiotic. Wockhardt Ltd....
BioCentury | Sep 15, 2014
Clinical News

WCK 771 regulatory update

...pneumonia (HAP). Early next year, Wockhardt plans to start Phase III testing of both compounds. Wockhardt...
...WCK 771 is an IV tricyclic fluoroquinolone, and WCK 2349 is an oral broad-spectrum antibiotic. Wockhardt Ltd....
BioCentury | Sep 16, 2013
Company News

Avanir, Wockhardt neurology news

...Avanir and Wockhardt settled a 2011 suit alleging Wockhardt's ANDA for a generic version of Nuedexta...
...treat pseudobulbar affect (PBA) infringes Avanir's U.S. Patent Nos. 7,659,282 and RE38,115. Under the settlement, Wockhardt...
...BioCentury, Aug. 22, 2011 & Sept. 9, 2013). Avanir Pharmaceuticals Inc. (NASDAQ:AVNR), Aliso Viejo, Calif. Wockhardt Ltd....
BioCentury | Aug 5, 2013
Company News

Orion, Mylan, Novartis neurology news

...7, 2012). In 2010, Orion granted Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA, Mumbai, India) and Wockhardt Ltd....
...April 1, 2012, while its rights to market other strengths begin on Oct. 2, 2012. Wockhardt's...
BioCentury | Jul 30, 2012
Company News

Cobalt Laboratories Inc., Sun Pharmaceuticals Industries Ltd., Teva, Actavis, Lupin, Mylan Pharmaceuticals Inc., Novartis, Pfizer, Wockhardt neurology news

...NASDAQ:MYL), Canonsburg, Pa. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Pfizer Inc. (NYSE:PFE), New York, N.Y. Wockhardt Ltd....
BioCentury | May 7, 2012
Company News

Orion, Mylan, Novartis neurology news

...April 2). In 2010, Orion granted Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA, Mumbai, India) and Wockhardt Ltd....
...April 1, 2012, while its rights to market other strengths begin on Oct. 2, 2012. Wockhardt's...
Items per page:
1 - 10 of 34
BioCentury | Apr 7, 2017
Company News

Jazz, Hikma deal

...the last of which expires in March 2033. It has already settled patent litigation with Wockhardt Ltd....
BioCentury | Apr 6, 2017
Company News

Jazz, Hikma settle Xyrem patent litigation

...the last of which expires in March 2033. It has already settled patent litigation with Wockhardt Ltd....
BioCentury | Oct 28, 2016
Company News

Cempra falls on FDA's manufacturing concerns

...said it believes FDA's concerns are related to GMP systems at "several" facilities operated by Wockhardt Ltd....
BioCentury | May 16, 2016
Analyst Picks & Changes

Analyst picks & changes

...from $137 after Jazz settled two patent infringement suits regarding Xyrem sodium oxybate. Jazz granted Wockhardt Ltd....
BioCentury | Sep 15, 2014
Clinical News

WCK 2349 regulatory update

...pneumonia (HAP). Early next year, Wockhardt plans to start Phase III testing of both compounds. Wockhardt...
...WCK 771 is an IV tricyclic fluoroquinolone, and WCK 2349 is an oral broad-spectrum antibiotic. Wockhardt Ltd....
BioCentury | Sep 15, 2014
Clinical News

WCK 771 regulatory update

...pneumonia (HAP). Early next year, Wockhardt plans to start Phase III testing of both compounds. Wockhardt...
...WCK 771 is an IV tricyclic fluoroquinolone, and WCK 2349 is an oral broad-spectrum antibiotic. Wockhardt Ltd....
BioCentury | Sep 16, 2013
Company News

Avanir, Wockhardt neurology news

...Avanir and Wockhardt settled a 2011 suit alleging Wockhardt's ANDA for a generic version of Nuedexta...
...treat pseudobulbar affect (PBA) infringes Avanir's U.S. Patent Nos. 7,659,282 and RE38,115. Under the settlement, Wockhardt...
...BioCentury, Aug. 22, 2011 & Sept. 9, 2013). Avanir Pharmaceuticals Inc. (NASDAQ:AVNR), Aliso Viejo, Calif. Wockhardt Ltd....
BioCentury | Aug 5, 2013
Company News

Orion, Mylan, Novartis neurology news

...7, 2012). In 2010, Orion granted Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA, Mumbai, India) and Wockhardt Ltd....
...April 1, 2012, while its rights to market other strengths begin on Oct. 2, 2012. Wockhardt's...
BioCentury | Jul 30, 2012
Company News

Cobalt Laboratories Inc., Sun Pharmaceuticals Industries Ltd., Teva, Actavis, Lupin, Mylan Pharmaceuticals Inc., Novartis, Pfizer, Wockhardt neurology news

...NASDAQ:MYL), Canonsburg, Pa. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Pfizer Inc. (NYSE:PFE), New York, N.Y. Wockhardt Ltd....
BioCentury | May 7, 2012
Company News

Orion, Mylan, Novartis neurology news

...April 2). In 2010, Orion granted Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA, Mumbai, India) and Wockhardt Ltd....
...April 1, 2012, while its rights to market other strengths begin on Oct. 2, 2012. Wockhardt's...
Items per page:
1 - 10 of 34